1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is 112,78€ (+106,82%). The median is 120,22€ (+120,47%).
| Buy |
7 |
| Hold |
4 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 0.00 | - |
| Gross profit | 0.00 | - |
| Net profit | −14.22m | 710,86% |
| EBITDA | −12.71m | 637,37% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | 138.62m€ |
Number of shares | 2.75m |
52-week high/low | 206,10€ - 6,01€ |
| Dividends | No |
Beta | 3,34 |
P/E ratio | −1,44 |
PEG ratio | −0,02 |
P/B ratio | 1,70 |
P/S ratio | 0,00 |
Company profile
| Name | Spruce Biosciences |
| CEO | Javier Szwarcberg |
| Headquarters | South San Francisco,
ca USA |
| Sector | Materials |
| Industry | Chemicals |
| Employees | 22 |
Discover assets
Shareholders of Spruce Biosciences also invest in the following assets
